Study: Cholesterol was lowered with an oral PCSK9 inhibitor.

Published Date: 08 Mar 2023

A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...

Read Full News

Latest News

From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class Linda Stein Gold, MD, Andrew Blauvelt, MD

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD Eric Simpson, MD, MCR

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD Aaron R. Mangold, MD

Aaron Mangold, MD, discusses phase 2 BEACON data on brepocitinib, a TYK2/JAK1 inhibitor, in cutaneous sarcoidosis presented at EADV 2026.

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

EADV Congress 2026: 9 Late Breakers to Know

EADV Congress 2026: 9 Late Breakers to Know

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Todays Updates

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Todays Updates

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Latest News

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

Aaron Mangold, MD, discusses phase 2 BEACON data on brepocitinib, a TYK2/JAK1 inhibitor, in cutaneous sarcoidosis presented at EADV 2026.

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

EADV Congress 2026: 9 Late Breakers to Know

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

News All Time

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Tips on Optimizing HS Biologics, Combinations, and Surgery

Tips on Optimizing HS Biologics, Combinations, and Surgery

Conference Preview: Fall Clinical Dermatology Conference 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Corticosteroid Stewardship in Dermatology is Not Steroid Avoidance, With Adam Friedman, MD Adam Friedman, MD, FAAD

Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.

Patient Perspective on Topical Steroid Withdrawal, With Briana Banos Briana Banos

Topical steroid withdrawal advocate Briana Banos urged clinicians to stay curious and treat patients as experts on their own bodies.

Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Recommended News For You

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.

EHA: European Hematology Association

Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test

Tennessee Pharmacies Sell Potent Ivermectin Pushed by Anti-Vaccine Doctor

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

Young adults who are obese are at risk for 17 different types of cancer in the future.

Recommended Articles For You

Pharmacokinetic Optimization of Combination Cancer Therapy 

The Lowdown on Darbepoetin: Understanding Its Uses and Side Effects  

Chondroma: What it is and How it Affects Your Health  

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In patients with prostate cancer, second-generation antiandrogens may worsen fatigue, falls, and cognitive decline.

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

I Watched My Friend Choose Death. Physician-Assisted Suicide Needs More Guardrails.

4.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

5.

Specific suicidal patterns mark the highest risk.

1.

Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes

2.

Optimizing Oncology Practice Revenue: Billing Software, Payer Trends, and Financial Navigation Tools

3.

A Comprehensive Guide to Using an ABG Calculator for Accurate Diagnosis

4.

Antibody-Based Protein Degraders: Mechanisms, Clinical Applications, and Future Directions

5.

Advancing Cancer Treatment: Precision Pharmaceutical Care in Oncohematology

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Navigating the Complexities of Ph Negative ALL - Part VIII

2.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

3.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

5.

Blood Clotting Disorders Explained

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot